Cereno Scientific participating at ESC Congress 2024 to continue building presence in the global cardiovascular community
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, will participate at the ESC (European Society of Cardiology) Congress in London, August 30–September 2, 2024."We look forward to meeting with leaders within the global cardiovascular community at ESC to continue raising awareness about our portfolio of innovative drug candidates, learn about the most recent advances in the cardiovascular field and expand our network among academic and industry actors. With important milestones coming up, the